Tags

Type your tag names separated by a space and hit enter

Prevalence of inadequate vitamin d status and associated factors in children with cystic fibrosis.
Nutr Clin Pract 2015; 30(1):111-6NC

Abstract

BACKGROUND

This study aimed to determine the prevalence of inadequate serum 25-hydroxyvitamin D (25(OH)D) levels in a pediatric Canadian cystic fibrosis (CF) population and to assess the effectiveness of a vitamin D supplementation protocol on improving vitamin D status. A secondary objective was to analyze factors that may be associated with inadequate 25(OH)D levels.

METHODS

Vitamin D supplementation, 25(OH)D levels, and factors hypothesized to be associated with 25(OH)D levels were collected through a retrospective chart review (2010 and 2011) of 96 patients (1-18 years) at one CF clinic in Canada. Adequacy of 25(OH)D was set at ≥75 nmol/L. Patients with inadequate 25(OH)D levels in 2010 were prescribed an additional 1000 IU/d for levels <60 nmol/L or 400 IU/d for levels 60-75 nmol/L.

RESULTS

Inadequate 25(OH)D levels were observed in 26% of patients in 2010 and 23% in 2011. After supplementation was increased for those with inadequate 25(OH)D levels in 2010 (n = 20), a significant increase in 25(OH)D levels was observed in 2011 (P = .03). Adequate status was achieved in 50% of these patients (n = 10). Age was significantly negatively associated with 25(OH)D levels in both years (P = .002). Percentage of forced expiratory volume in 1 second was significantly positively associated with 25(OH)D levels in 2011 (P = .03).

CONCLUSION

While vitamin D supplementation was effective at increasing serum 25(OH)D, this protocol did not achieve optimal serum 25(OH)D levels in 25% of the population. Increasing age had the strongest association with 25(OH)D. Current supplementation protocols may require reevaluation based on emerging evidence and revised Cystic Fibrosis Foundation guidelines.

Authors+Show Affiliations

Faculty of Agriculture, Life and Environmental Sciences, University of Alberta, Edmonton, Alberta, Canada Alberta Health Services, Edmonton, Alberta, Canada.Faculty of Agriculture, Life and Environmental Sciences, University of Alberta, Edmonton, Alberta, Canada Alberta Health Services, Edmonton, Alberta, Canada.Alberta Health Services, Edmonton, Alberta, Canada.Faculty of Agriculture, Life and Environmental Sciences, University of Alberta, Edmonton, Alberta, Canada.Alberta Health Services, Edmonton, Alberta, Canada.Alberta Health Services, Edmonton, Alberta, Canada bodil.larsen@albertahealthservices.ca.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25550329

Citation

Norton, Laura, et al. "Prevalence of Inadequate Vitamin D Status and Associated Factors in Children With Cystic Fibrosis." Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition, vol. 30, no. 1, 2015, pp. 111-6.
Norton L, Page S, Sheehan M, et al. Prevalence of inadequate vitamin d status and associated factors in children with cystic fibrosis. Nutr Clin Pract. 2015;30(1):111-6.
Norton, L., Page, S., Sheehan, M., Mazurak, V., Brunet-Wood, K., & Larsen, B. (2015). Prevalence of inadequate vitamin d status and associated factors in children with cystic fibrosis. Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition, 30(1), pp. 111-6. doi:10.1177/0884533614562839.
Norton L, et al. Prevalence of Inadequate Vitamin D Status and Associated Factors in Children With Cystic Fibrosis. Nutr Clin Pract. 2015;30(1):111-6. PubMed PMID: 25550329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of inadequate vitamin d status and associated factors in children with cystic fibrosis. AU - Norton,Laura, AU - Page,Sarah, AU - Sheehan,Melissa, AU - Mazurak,Vera, AU - Brunet-Wood,Kim, AU - Larsen,Bodil, Y1 - 2014/12/30/ PY - 2015/1/1/entrez PY - 2015/1/1/pubmed PY - 2016/1/12/medline KW - cystic fibrosis KW - pediatrics KW - vitamin D KW - vitamin D deficiency SP - 111 EP - 6 JF - Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition JO - Nutr Clin Pract VL - 30 IS - 1 N2 - BACKGROUND: This study aimed to determine the prevalence of inadequate serum 25-hydroxyvitamin D (25(OH)D) levels in a pediatric Canadian cystic fibrosis (CF) population and to assess the effectiveness of a vitamin D supplementation protocol on improving vitamin D status. A secondary objective was to analyze factors that may be associated with inadequate 25(OH)D levels. METHODS: Vitamin D supplementation, 25(OH)D levels, and factors hypothesized to be associated with 25(OH)D levels were collected through a retrospective chart review (2010 and 2011) of 96 patients (1-18 years) at one CF clinic in Canada. Adequacy of 25(OH)D was set at ≥75 nmol/L. Patients with inadequate 25(OH)D levels in 2010 were prescribed an additional 1000 IU/d for levels <60 nmol/L or 400 IU/d for levels 60-75 nmol/L. RESULTS: Inadequate 25(OH)D levels were observed in 26% of patients in 2010 and 23% in 2011. After supplementation was increased for those with inadequate 25(OH)D levels in 2010 (n = 20), a significant increase in 25(OH)D levels was observed in 2011 (P = .03). Adequate status was achieved in 50% of these patients (n = 10). Age was significantly negatively associated with 25(OH)D levels in both years (P = .002). Percentage of forced expiratory volume in 1 second was significantly positively associated with 25(OH)D levels in 2011 (P = .03). CONCLUSION: While vitamin D supplementation was effective at increasing serum 25(OH)D, this protocol did not achieve optimal serum 25(OH)D levels in 25% of the population. Increasing age had the strongest association with 25(OH)D. Current supplementation protocols may require reevaluation based on emerging evidence and revised Cystic Fibrosis Foundation guidelines. SN - 1941-2452 UR - https://www.unboundmedicine.com/medline/citation/25550329/Prevalence_of_inadequate_vitamin_d_status_and_associated_factors_in_children_with_cystic_fibrosis_ L2 - https://doi.org/10.1177/0884533614562839 DB - PRIME DP - Unbound Medicine ER -